ZLDPF (Zealand Pharma AS) Moat Score: 5/10 (As of Jun. 29, 2026)


ZLDPF Zealand Pharma AS ZLDPF
62 GF Score
Price $42.89
GF Value $1,929.01
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Zealand Pharma AS Moat Score?

Zealand Pharma AS ZLDPF 62 Moat Score is 5 as of Jun. 29, 2026. GuruFocus rates ZLDPF with a GF Score™ of 62/100 and a GF Value™ of $1,929.01 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,401 Biotechnology companies, Zealand Pharma AS ranks better than 96.72% on this metric.

Zealand Pharma AS has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Zealand Pharma AS has Narrow Moat: Zealand Pharma AS has a solid narrow moat due to its proprietary drug formulations and strong R&D capabilities. The company benefits from regulatory barriers and some customer loyalty, but lacks the market dominance and brand strength needed for a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Zealand Pharma AS might have Narrow Moat - Solid narrow moat.

Zealand Pharma AS  (OTCPK:ZLDPF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Zealand Pharma AS Moat Score Related Terms

ZLDPF vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Zealand Pharma AS's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zealand Pharma AS Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Moat Score distribution charts can be found below:

* The bar in red indicates where Zealand Pharma AS's Moat Score falls into.


ZLDPF
62GF Score
Zealand Pharma AS ZLDPF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Zealand Pharma AS (ZLDPF) has a Moat Score of 5 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Zealand Pharma AS ranks #46 out of 1401 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Zealand Pharma AS's Moat Score too high?
Zealand Pharma AS's current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. Zealand Pharma AS's value of 5 is 150% above this industry median. Based on the distribution chart, Zealand Pharma AS ranks #46 out of 1401 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zealand Pharma AS has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zealand Pharma AS ranks #46 out of 1401 companies for Moat Score. This places Zealand Pharma AS in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Zealand Pharma AS's value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zealand Pharma AS's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zealand Pharma AS's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (ZLDPF) is currently considered Possible Value Trap. The stock's GF Value™ is $1,929.01, compared to a current price of $42.89 — trading 97.8% below its estimated fair value. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. Zealand Pharma AS's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPF), the current Moat Score is 5 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zealand Pharma AS (ZLDPF) Overvalued in 2026?

Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued. The current stock price of $42.89 is trading 97.8% below its estimated GF Value™ of $1,929.01. GuruFocus considers Zealand Pharma AS to be Possible Value Trap.

Key valuation signals for ZLDPF:

  • Moat Score: 5
  • GF Value™: $1,929.01 vs. price of $42.89 (97.8% below fair value)
  • GF Score™: 62/100 with 3 warning signs
  • Industry Position: 150% above the Biotechnology median (#46 of 1401)

No single metric tells the full story. See the ZLDPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
62GF Score

Get the complete analysis for ZLDPF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.89
Price
$1,929.01
GF Value